‘The very last thing a drug regulator wishes to be able to say is, like Lord Byron (1788-1824), on the publication of his poem Childe Harold’s Pilgrimage, ‘I awoke one morning and found myself famous.’
The twelfth edition of this long-established textbook of clinical pharmacology (first published in 1960) continues its fine tradition of balancing science and practice for improved evidence-based drug therapy and good prescribing in therapeutic settings increasingly complicated by intercurrent disease and polypharmacy.
‘The very last thing a drug regulator wishes to be able to say is, like Lord Byron (1788-1824), on the publication of his poem Childe Harold’s Pilgrimage, ‘I awoke one morning and found myself famous.’
1. Chapter 1: Introduction - p. iii 2. Chapter 2: Clinical pharmacology - p. iii 3. Chapter 3: Topics in drug therapy - p. iii 4. Chapter 4: Discovery and development of drugs - p. iii 5. Chapter 5: Evaluation of drugs in humans - p. iii 6. Chapter 6: Health technology assessment - p. iii 7. Chapter 7: Regulation of medicines - p. iii 8. Chapter 8: Classification and naming of drugs - p. iii 9. Section 2: From pharmacology to toxicology - p. iii 10. Chapter 9: Introduction - p. iii 11. Chapter 10: General pharmacology - p. iii 12. Chapter 11: Unwanted effects and adverse drug reactions - p. iii 13. Chapter 12: Poisoning, overdose, antidotes - p. iii 14. Chapter 13: Drug dependence - p. iii 15. Section 3: Infection and inflammation - p. iii 16. Chapter 14: Introduction - p. iii 17. Chapter 15: Chemotherapy of infections - p. iii 18. Chapter 16: Antibacterial drugs - p. iii 19. Chapter 17: Chemotherapy of bacterial infections - p. iii 20. Chapter 18: Viral, fungal, protozoal and helminthic infections - p. iii 21. Chapter 19: Drugs for inflammation and joint disease - p. iii 22. Chapter 20: Drugs and the skin - p. iii 23. Section 4: Nervous system - p. iii 24. Chapter 21: Introduction - p. iii 25. Chapter 22: Pain and analgesics - p. iii 26. Chapter 23: Anaesthesia and neuromuscular block - p. iii 27. Chapter 24: Psychotropic drugs - p. iii 28. Chapter 25: Neurological disorders – epilepsy, Parkinson's disease and multiple sclerosis - p. g0060 29. Section 5: Cardiorespiratory and renal systems - p. g0060 30. Chapter 26: Introduction - p. g0060 31. Chapter 27: Cholinergic and antimuscarinic (anticholinergic) mechanisms and drugs - p. g0060 32. Chapter 28: Adrenergic mechanisms and drugs - p. g0060 33. Chapter 29: Arterial hypertension, angina pectoris, myocardial infarction and heart failure - p. g0060 34. Chapter 30: Cardiac arrhythmia - p. g0060 35. Chapter 31: Hyperlipidaemias - p. g0060 36. Chapter 32: Kidney and genitourinary tract - p. g0060 37. Chapter 33: Respiratory system - p. g0060 38. Section 6: Blood and neoplastic disease - p. g0060 39. Chapter 34: Introduction - p. g0060 40. Chapter 35: Drugs and haemostasis - p. g0060 41. Chapter 36: Red blood cell disorders - p. g0060 42. Chapter 37: Neoplastic disease and immunosuppression - p. g0060 43. Section 7: Gastrointestinal system - p. g0060 44. Chapter 38: Introduction - p. g0060 45. Chapter 39: Oesophagus, stomach and duodenum - p. g0060 46. Chapter 40: Intestines - p. g0060 47. Chapter 41: Liver and biliary tract - p. g0060 48. Section 8: Endocrine system, metabolic conditions - p. g0060 49. Chapter 42: Introduction - p. g0060 50. Chapter 43: Adrenal corticosteroids, antagonists, corticotropin - p. g0060 51. Chapter 44: Diabetes mellitus, insulin, oral antidiabetes agents, obesity - p. g0060 52. Chapter 45: Thyroid hormones, antithyroid drugs - p. g0060 53. Chapter 46: Hypothalamic, pituitary and sex hormones - p. g0060 54. Chapter 47: Vitamins, calcium, bone - p. g0060 55. Index - p. g0060
No hay muestra disponible
No hay ficha técnica disponible
‘The very last thing a drug regulator wishes to be able to say is, like Lord Byron (1788-1824), on the publication of his poem Childe Harold’s Pilgrimage, ‘I awoke one morning and found myself famous.’
The twelfth edition of this long-established textbook of clinical pharmacology (first published in 1960) continues its fine tradition of balancing science and practice for improved evidence-based drug therapy and good prescribing in therapeutic settings increasingly complicated by intercurrent disease and polypharmacy.
‘The very last thing a drug regulator wishes to be able to say is, like Lord Byron (1788-1824), on the publication of his poem Childe Harold’s Pilgrimage, ‘I awoke one morning and found myself famous.’
1. Chapter 1: Introduction - p. iii 2. Chapter 2: Clinical pharmacology - p. iii 3. Chapter 3: Topics in drug therapy - p. iii 4. Chapter 4: Discovery and development of drugs - p. iii 5. Chapter 5: Evaluation of drugs in humans - p. iii 6. Chapter 6: Health technology assessment - p. iii 7. Chapter 7: Regulation of medicines - p. iii 8. Chapter 8: Classification and naming of drugs - p. iii 9. Section 2: From pharmacology to toxicology - p. iii 10. Chapter 9: Introduction - p. iii 11. Chapter 10: General pharmacology - p. iii 12. Chapter 11: Unwanted effects and adverse drug reactions - p. iii 13. Chapter 12: Poisoning, overdose, antidotes - p. iii 14. Chapter 13: Drug dependence - p. iii 15. Section 3: Infection and inflammation - p. iii 16. Chapter 14: Introduction - p. iii 17. Chapter 15: Chemotherapy of infections - p. iii 18. Chapter 16: Antibacterial drugs - p. iii 19. Chapter 17: Chemotherapy of bacterial infections - p. iii 20. Chapter 18: Viral, fungal, protozoal and helminthic infections - p. iii 21. Chapter 19: Drugs for inflammation and joint disease - p. iii 22. Chapter 20: Drugs and the skin - p. iii 23. Section 4: Nervous system - p. iii 24. Chapter 21: Introduction - p. iii 25. Chapter 22: Pain and analgesics - p. iii 26. Chapter 23: Anaesthesia and neuromuscular block - p. iii 27. Chapter 24: Psychotropic drugs - p. iii 28. Chapter 25: Neurological disorders – epilepsy, Parkinson's disease and multiple sclerosis - p. g0060 29. Section 5: Cardiorespiratory and renal systems - p. g0060 30. Chapter 26: Introduction - p. g0060 31. Chapter 27: Cholinergic and antimuscarinic (anticholinergic) mechanisms and drugs - p. g0060 32. Chapter 28: Adrenergic mechanisms and drugs - p. g0060 33. Chapter 29: Arterial hypertension, angina pectoris, myocardial infarction and heart failure - p. g0060 34. Chapter 30: Cardiac arrhythmia - p. g0060 35. Chapter 31: Hyperlipidaemias - p. g0060 36. Chapter 32: Kidney and genitourinary tract - p. g0060 37. Chapter 33: Respiratory system - p. g0060 38. Section 6: Blood and neoplastic disease - p. g0060 39. Chapter 34: Introduction - p. g0060 40. Chapter 35: Drugs and haemostasis - p. g0060 41. Chapter 36: Red blood cell disorders - p. g0060 42. Chapter 37: Neoplastic disease and immunosuppression - p. g0060 43. Section 7: Gastrointestinal system - p. g0060 44. Chapter 38: Introduction - p. g0060 45. Chapter 39: Oesophagus, stomach and duodenum - p. g0060 46. Chapter 40: Intestines - p. g0060 47. Chapter 41: Liver and biliary tract - p. g0060 48. Section 8: Endocrine system, metabolic conditions - p. g0060 49. Chapter 42: Introduction - p. g0060 50. Chapter 43: Adrenal corticosteroids, antagonists, corticotropin - p. g0060 51. Chapter 44: Diabetes mellitus, insulin, oral antidiabetes agents, obesity - p. g0060 52. Chapter 45: Thyroid hormones, antithyroid drugs - p. g0060 53. Chapter 46: Hypothalamic, pituitary and sex hormones - p. g0060 54. Chapter 47: Vitamins, calcium, bone - p. g0060 55. Index - p. g0060
No hay muestra disponible
No hay ficha técnica disponible
